| Literature DB >> 35342843 |
Deganta Ghosh1, Sagardeep Dey1, Himanko Chakraborty1, Sneha Mukherjee1, Ankita Halder1, Akash Sarkar1, Pallab Chakraborty2, Rajdeep Ghosh3, Joy Sarkar1.
Abstract
The main reason for the growth of mucormycosis in people with Coronavirus disease-2019 (COVID-19) is mainly produced by Rhizopus spp. The infective mechanisms and issues recognized in Rhizopus spp. are the cell wall, germination proteins, and enzymes assisted to iron sequestration, CotH protein, and positive regulation of the GRP78 cell receptor. Mucormycosis is mainly caused by the Rhizopus spp. such as R. oryzae, R. microsporus, R. arrhizus, R. homothallicus, etc. that are gifted to numerous host defense mechanisms and attribute to the endothelium via specific receptors, GRP78 simplifying their endocytosis and angio-invasion. Factors such as hyperglycemia, elevated iron concentrations, and ketoacidosis have been shown to contribute to the pathogenesis in the tentative situation. The analytical data of 'black fungus disease' or 'mucormycosis', specify India reported for about 42.3% of published cases, followed by the USA about 16.9%, Iraq, Bangladesh, Iran, Paraguay, and 1 case each from Brazil, Mexico, Italy, UK, China, France, Uruguay, Turkey, and Austria. The COVID-19 infection is maybe a predisposing factor for mucormycosis and is related to a high mortality rate. Early recognition and restriction of hyperglycemia, liposomal amphotericin B, and surgical debridement are the bases in the successful managing of mucormycosis.Entities:
Keywords: COVID-19; Corticosteroid; Diabetics; Mucormycosis; Rhizopus
Year: 2022 PMID: 35342843 PMCID: PMC8934183 DOI: 10.1016/j.cegh.2022.101013
Source DB: PubMed Journal: Clin Epidemiol Glob Health ISSN: 2213-3984
Fig. 1A global presentation of the number of published case reports of Coronavirus disease 2019 (COVID-19) associated mucormycosis (till May 2021). (a) The color gradient segment of the map indicates the number of absolute cases reported worldwide, where the dark-colored portion represents the higher number of cases, while the light-colored portion represents a smaller number. (b) A schematic presentation showing the variation of the number of reported cases in different countries.20, 21, 22, 23
A brief number of cases of Coronavirus disease 2019 (COVID-19) associated mucormycosis reported worldwide.
| Reported Area | Total No. of case | Age/Sex | Underlying Disease | Disease Type | Verified COVID-19 | Medicine used for COVID-19 | Fungal culture | Clinical Outcomes | Reference | |
|---|---|---|---|---|---|---|---|---|---|---|
| DM/DKA/T1DM/T2DM | Cancer | |||||||||
| India | 25 | 23–78 | DM-24 (32–78) | No All | Rhino-orbital: 23, 60 | Confirmed | Steroid-51, 37, 43, 56, 78, 49, 60, 55, 38, 64, 60, 59F, 72 | Positive ( | Expired-10 | |
| Bangladesh | 3 | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | |
| USA | 10 | 33–79 | DM-36, 48, 79, 68 | No- 9 (44F Yes) | Rhino-orbital: 33, 60 | Confirmed | Steroid- 36, 44, 48, 49, 60, 41, 79, 56, 68 | Positive all (79 M & 44F | Expired-6 | |
| UK | 1 | 22 | No | No | Pulmonary | Confirmed | Not applied | Positive | Expired | |
| Brazil | 1 | 86 | No | No | Gastrointestinal | Confirmed | Not applied | Positive ( | Expired | |
| Italy | 1 | 66 | No | No | Pulmonary | Confirmed | Not applied | Positive ( | Expired | |
| France | 1 | 55 | No | Yes | Pulmonary | Confirmed | Not applied | Positive ( | Expired | |
| Iran | 4 | 40–61 | DM-44, 54 | No-All | Rhino-orbital: 61, 54 | Confirmed | Steroid- 40, 44, 54,61 | Positive ( | Expired-2 | |
| China | 1 | 32 | No | No | Rhino-cerebral | Confirmed | Not applied | Positive | Expired | |
| Mexico | 1 | 24 | DM-No | No | Rhino-orbital | Confirmed | Not applied | Positive ( | Expired | |
| Austria | 1 | 53 | No | Yes | Pulmonary | Confirmed | Not applied | Positive ( | Expired | |
| Turkey | 1 | 56 | DM-56 | No | Rhino-orbital sinusitis | Confirmed | Steroid- 56 | Positive ( | Expired | |
| Uruguay | 1 | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Recovered | |
| Paraguay | 2 | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | |
| Iraq | 5 | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | |
| Chile | 1 | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | |
M: Male, F: Female, DM: Diabetes mellitus, DKA: Diabetic ketoacidosis, T1DM: Type 1 diabetes mellitus, T2DM: Type 2 diabetes mellitus, COVID-19: Coronavirus disease 2019.
Fig. 2An illustrative presentation on the number of cases of Coronavirus disease 2019 (COVID-19) associated mucormycosis reported in the different States of India (till September of 2021). (a) The colors provided in the different geographical area represents the variation in the number of cases. (b) A schematic presentation on the number of deaths in different States of India due to mucormycosis. (c) Up-to-date state-wise statistical indication of COVID-19 cases along with mucormycosis cases of India, (Link 6; Link 7; Link 8).
A precise of cases reported in India on Coronavirus disease 2019 (COVID-19) associated mucormycosis.
| Case No. | Age/Sex | Reported Area | Occurrence of fungal colonies during microscopy | Causative Agent | Disease Type | Underlying Disease | Infected internal body parts | Symptoms | Clinical outcomes | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Case-1 | 32/F | Mangalore | Positive | Paranasal Mucormycosis | Diabetes mellitus, left eye complete ptosis, facial problem | Sinus and orbit | Orbital apex syndrome Rapidly lost eye vision | Recovered but no improvement in vision | ||
| Case-2 | 60/M | Mumbai | Positive | Rhino-orbital Mucormycosis | Diabetes mellitus, Lung disease | Sinus and orbit | orbital swelling, headache, nosebleed | Expired | ||
| Case-3 | 38/M | Mumbai | Positive | Sino-orbital Mucormycosis | Diabetes mellitus | Sinus and orbit | Swelling and pain in the left eye | Recovered | ||
| Case-4 | 72/M | Hyderabad | Positive | Pulmonary Mucormycosis | Diabetes mellitus, hypertension | Lungs | Streaky hemoptysis | The patient is not improving | ||
| Case-5 | 40/F | Mangalore | Positive | Rhino orbital cerebral Mucormycosis | Diabetes mellitus | Sinus, orbit, and CNS | Swelling of the left eye and facial pain, rhinitis | Recovered | ||
| Case-6 | 38/M | Bangalore | Positive | Rhino orbital cerebral Mucormycosis | Diabetes mellitus | Orbit, sinus | Right eye pain and chemosis | Expired | ||
| Case-7 | 51/F | Mumbai | Positive | Rhino orbital cerebral Mucormycosis | Diabetes, Hypothyroidism | Eye, sinus, and CNS | Left side facial pain, nose block, periorbital pain, and headache | Recovered | ||
| Case-8 | 45/M | Puducherry | Positive | Rhino orbital cerebral Mucormycosis | Diabetes mellitus, Hypertension, CKD | Eye damage, sinus, and CNS | Impairment of right eye vision | Recovered | ||
| Case-9 | 56/M | Bangalore | Positive | Rhino orbital cerebral Mucormycosis | CKD, diabetes, hypertension, hyperthyroidism | Eye conjunctiva, brain | Right eye swelling | Expired | ||
| Case-10 | 78/M | Bangalore | Positive | Rhino orbital cerebral Mucormycosis | Diabetes and hypertension | Sinus, orbit, and CNS | Holocranial headache | Expired | ||
| Case-11 | 43/M | Bangalore | Positive | Rhino-sinusitis Mucormycosi | Diabetes mellitus, CLD | Sinus, nasal passages, oral cavity, and brain | Dryness and cresting in the nasal cavity | Recovered | ||
| Case-12 | 60/M | Delhi | Positive | Rhino-sinusitis Mucormycosis | Diabetes mellitus, deranged kidney function | Sinus and brain | Periorbital swelling, chemosis, restricted eye movement | Expired | ||
| Case-13 | 64/M | Delhi | Positive | Rhino-sinusitis Mucormycosis | Diabetes mellitus, renal function failure | Sinus, nasal passages, oral cavity, and brain | Proptosis of the eye with Periorbital discoloration, blackening of the middle turbinate. | Expired | ||
| Case-14 | 67/M | Not Reported | Positive | Rhino orbital cerebral Mucormycosis | Hypertension | Cornia, conjunctiva, eyelids, optic nerve damage | High fever, dizziness, blurred vision | Recovered | ||
| Case-15 | 49/M | Not Reported | Positive | Rhino-sinusitis Mucormycosis | Diabetes mellitus, problem in breathing | Sinus, brain, and nasal passages | High fever, facial swelling | Recovered | ||
| Case-16 | 23/M | Not Reported | Positive | Rhino-orbital Mucormycosis | Diabetes mellitus, hypertension | Sinus and orbit | High fever, headache, periorbital pain, facial pain | Expired | ||
| Case-17 | 59/F | Delhi | Positive | Rhino-sinusitis Mucormycosis | Diabetes | Sinus and brain | High fever, facial swelling, blackening of turbinate | Recovered | ||
| Case-18 | 62/M | Not Reported | Positive | Rhino orbital Mucormycosis | Diabetes mellitus, High pressure | Sinus and orbit | Periorbital pain, blurred vision, and headache | Expired | ||
| Case-19 | 43/M | Not Reported | Positive | Pulmonary mucormycosis | Diabetes mellitus, problems in renal area | Lung | Facial swelling, infection in the lung, high fever | Recovered | ||
| Case 20 | 32/M | Hyderabad | Positive | Pulmonary Mucormycosis | Diabetes mellitus | Lung | High fever, nasal tract infection, headache, infection in lung | Recovered | ||
| Case-21 | 60/M | Mumbai | Positive | Rhino orbital Mucormycosis | Diabetes mellitus | Sinus and orbit | Periorbital pain, blurred vision | Expired | ||
| Case-22 | 55/M | Chandigarh | Positive | Pulmonary Mucormycosis | Diabetes mellitus, End-stage kidney disease | Lung | Facial swelling, infection in the lung, high fever | Recovered | ||
| Case-23 | 59/M | Delhi | Positive | Rhino sinusitis Mucormycosis | Diabetes mellitus, High pressure, Coronary artery disease | Sinus and brain | High fever and facial swelling, blackening of turbinate | Expired | ||
| Case-24 | 56/M | Bangalore | Positive | Rhino orbital cerebral Mucormycosis | Diabetes mellitus | Cornia, conjunctiva, eyelids, optic nerve damage | Right eye pain and gradual loss of vision | Loss of follow up | ||
| Case-25 | 37/M | Not Reported | Positive | Rhino orbital cerebral Mucormycosis | Diabetes mellitus | Cornia, conjunctiva, eyelids, optic nerve damage | Pain and bleeding from gums | Recovered |
M: Male, F: Female, CKD: Chronic kidney disease, CLD: Chronic liver disease, CNS: Central nervous system.
Fig. 3An evanescent theory on the types of mucormycosis presenting their efficacious side on the Coronavirus disease 2019 (COVID-19) associated mucormycosis patients. The diagram represents rhino-orbital cerebral (36%) mucormycosis is the highest reported type in India followed by the rhino orbital (20%), pulmonary (16%), and paranasal (4%).,
Fig. 4Microscopic view of Rhizopus spp. under Lactophenol cotton blue (LCB) mount. (a–b) Compound microscopic view of Rhizopus sp. showing columella and brownish sporangia under ca.×100 and ca.× 450 magnification, respectively. (c) Compound microscopic view of Rhizopus sp. showing the hyphal region under ca.×100 magnification. (d) Compound microscopic view of Rhizopus sp. showing sporangiospores under ca.×450 magnification.
Fig. 5Diagram pictured the planned mechanisms for the immunopathogenesis of COVID-19 assisted mucormycosis in the immunocompromised diabetic individual,,(Created with). (a) In COVID-19 severity, (b) uncontrolled diabetes mellitus and overdrive of Corticosteroid drugs increases the vulnerability to Mucorales infection due to diabetic ketoacidosis (DKA) and hyperglycemia. (c) An elevation in the glucose level of the adipose tissue induces endoplasmic reticulum (ER) stress, cellular hypoxia, enhanced discharge of free fatty acids (FFA), reactive oxygen species (ROS), and generate cytokine storm. (d) A diversified range of the cytokines like interleukin-1 (IL-1β), tumor necrosis factor (TNF), and various types of chemokines are released to the cellular hypoxic environment. (e) These cytokines especially TNF-α recruits the proinflammatory M1 macrophages and (f) inhibits the activity of anti-inflammatory M2 macrophages. (g) The activated M1 macrophage again discharges more pro-inflammatory cytokines like IL-1β, FFA and generates ROS. (h) These FFA are also detected by TLR-4 in the tissue cells, initiating JNK-AP-I and IKK-NFkB (nuclear factor-kappa B) signalling. (i) Simultaneously, diabetic ketoacidosis (DKA) causes a low pH environment which ultimately enhances the cellular H+ ion level. (j) Due to the activity of hyperglycemia, iron-scavenging proteins like ferritin and transferrin show increased glycosylation in the blood vessel, which lowers their iron affinity. (k) Furthermore, in the attendance of an acidotic condition promoted by the creation of ketone bodies (e.g., β-hydroxybutyrate [BHB]), the low pH environment in the blood vessels substantially restricts transferrin's ability to chelate iron. (l) As a result, the accessibility of free iron in the blood vessel is stimulated whereas (m) the counts of IFN-γ, CD4+, CD8+, and T-cell are sharply declined. (n) A combination of free iron, glucose, and BHB triggers epithelial fungal adhesion and tissular hyphal growth or opportunistic fungal infection. (o) This combination causes a stress response in ER, which drives to overexpression of the GRP78 protein. (p) The MTJ-1 chaperone aids in the translocation of GRP78 proteins from ER to the cell surface. (q) Fungi battle with the host for the presence of iron in the siderophore system. (r) High glucose concentrations, free iron availability, and an acid microenvironment boost CotH expression on the fungal cell surface, facilitating GRP78/CotH3 contact for epithelial/endothelial invasion and fungal spread. (s) The connection between GRP78 and CotH is additionally aided by ROS, FFA, and cytokines. (t) Meanwhile, endothelial cells pursue to generate GRP78 in all partitions, and the hypha can connect with these proteins on the basal side and become internalized in the lumen of blood vessels. (u) They produce cell damage, thrombus formation, ischemia, prolonged hypoxia, tissue infarction, and finally necrosis by activating the external coagulation pathway.
Fig. 6Compound microscopic view of different types of fungal species. (a–b) Compound microscopic view of Aspergillus sp. showing perpendicular hyphal branching pattern under ca.×100 and ca.× 450 magnification, respectively. (c-d) Compound microscopic view of Fusarium sp. showing conidia with conidiospores and dichotomous hyphal branching pattern under ca.×100 and ca.× 450 magnification, respectively. (e-f) Compound microscopic view of Rhizopus sp. showing perpendicular hyphal branching pattern under ca.×100 and ca.× 450 magnification, respectively.
Fig. 7Illustration of mucormycosis infection spreading to the nasal vestibules, maxillary sinus, and brain. (a) Nasal endoscopic view, showing the location of mucormycosis. (b) The magnetic resonance imaging (MRI) scan of the head and sinuses showing the location of pus accumulation and inflammation of the maxillary sinus due to mucormycosis (T1 weighted and T2 weighted MRI scans).